Livanova PLC 8-K filings

LivaNova PLC reported robust second-quarter 2026 financial results, exceeding revenue expectations and prompting an increase in full-year guidance, alongside a significant supply chain agreement.

LivaNova PLC's 2026 Annual General Meeting saw overwhelming shareholder approval for all ten proposals, including director elections, executive compensation, auditor ratification, and share repurchase authorizations.

LivaNova PLC reported strong first-quarter 2026 results, with revenue growth of 14.3% and raised full-year guidance for both revenue and adjusted diluted EPS.

LivaNova PLC announced robust double-digit revenue growth for full-year 2025, alongside positive 2026 guidance and key regulatory approvals.

LivaNova PLC announced the resignation of its Senior Vice President, Chief Legal Officer, and Company Secretary, Michael Hutchinson, effective January 26, 2026.

LivaNova PLC reported strong third-quarter 2025 results with double-digit revenue growth and raised its full-year 2025 financial guidance across key metrics.

LivaNova PLC announced the appointment of Donald Zurbay, a seasoned healthcare executive, to its Board of Directors and Audit and Compliance Committee, effective September 4, 2025.

LivaNova PLC reported robust second-quarter 2025 financial results, exceeding expectations with double-digit revenue growth and increased profitability, leading to an upward revision of its full-year 2025 financial guidance.

LivaNova PLC shareholders overwhelmingly approved the Second Amended and Restated 2022 Incentive Award Plan and the 2025 Director Incentive Award Plan, alongside the re-election of all ten directors and other governance proposals, at their Annual General Meeting on June 11, 2025.

LivaNova PLC is challenging assertions from the Ministry of Ecological Transition, the Ministry of Economy and Finance, and the Prime Ministers Office regarding costs associated with the SNIA environmental liabilities case, despite a previous Italian Supreme Court ruling.

LivaNova PLC announced positive first-quarter 2025 results, featuring high-single-digit revenue growth and double-digit organic revenue growth, leading to an increase in full-year 2025 revenue guidance.

LivaNova PLC expects to record a $363 million liability due to an Italian Supreme Court decision regarding the SNIA litigation, but believes it has sufficient resources to cover the amount.

LivaNova PLC reports a 8.7% increase in full-year 2024 revenue and issues guidance for 2025, projecting continued growth.

The U.S. Centers for Medicare and Medicaid Services (CMS) will maintain the current reimbursement level for LivaNova's VNS Therapy for drug-resistant epilepsy (DRE), a decision the company is disappointed with but does not expect to impact its business.

LivaNova reported a robust third quarter with double-digit revenue growth and raised its full-year 2024 guidance.

LivaNova PLC has appointed Susan Podlogar, a seasoned executive with over 30 years of experience, to its Board of Directors and Compensation and Human Capital Management Committee.

LivaNova PLC's Chief Human Resources Officer, Trui Hebbelinck, will depart on September 30, 2024, initiating a period of garden leave.

LivaNova reported strong second-quarter 2024 results, with revenue growth of 9.6% on a constant-currency basis and increased full-year revenue and adjusted diluted earnings per share guidance.

LivaNova PLC's shareholders approved amendments to its incentive award plans and elected directors at the 2024 Annual General Meeting.

LivaNova reported a strong first quarter with double-digit revenue growth and increased its full-year revenue and earnings per share guidance.

LivaNova PLC has successfully issued $345 million in convertible senior notes due 2029 and repurchased $230 million of its existing notes for approximately $270.5 million.

LivaNova PLC has announced the pricing of a $300 million private offering of convertible senior notes due in 2029, along with related capped call transactions and a plan to repurchase existing notes.

LivaNova PLC plans to offer $300 million in convertible senior notes due 2029 in a private placement to qualified institutional buyers.

LivaNova PLC reported a 12.9% increase in full-year revenue and announced Vladimir A. Makatsaria as the new CEO, effective March 1, 2024.

LivaNova PLC has announced the appointment of Vladimir A. Makatsaria as its new Chief Executive Officer and a member of the Board of Directors, effective March 1, 2024.